Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Immuneering Corp Director's Dealing 2024

Mar 25, 2024

32973_dirs_2024-03-25_e3b172b7-ca2e-4e01-9e4a-ec11b2ece43f.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Immuneering Corp (IMRX)
CIK: 0001790340
Period of Report: 2024-03-22

Reporting Person: Brakewood Harold Eugene (Chief Business Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2024-03-22 Class A Common Stock P 3900 $2.568 Acquired 3900 Direct